Advertisement
News
Advertisement

Texas A & M System Awarded National Center for Innovation

Mon, 06/18/2012 - 12:31pm
Bio-Medicine.Org

COLLEGE STATION, Texas, June 18, 2012 /PRNewswire-USNewswire/ -- John Sharp, chancellor of The Texas A&M University System, today announced that the A&M System has been awarded a contract to develop one of three U.S. Department of Health and Human Services Centers for Innovation in Advanced Development and Manufacturing. The $285.6 million contract includes an initial investment of $176.6 million from the U.S. government, with the remainder cost-shared by commercial and academic proposal partners. 

"We have long served our nation and risen to defend our country against national security threats," said Sharp. "Our selection for this Center reflects that tradition and means we are enhancing the nation's ability to counter biological and pandemic threats, both known and unknown, with vaccines manufactured here in the United States. We would like to thank President Obama and his administration; we are honored to be selected and to have the Texas A&M System's unique capabilities leveraged to meet critical 21st-century challenges."

The Center will utilize rapid, nimble and flexible approaches to: (1) develop and manufacture vaccines to protect against pandemic influenza; (2) provide therapies in the event of chemical, biological, radiological, and nuclear threats; (3) perform advanced development, accelerating vaccines and other biosecurity products through pre-clinical and clinical development, leading to licensure; and, (4) train the next generation of professionals in areas required to sustain this national capability, including process engineering, pharmaceutical manufacturing, veterinary sciences, quality, and regulatory affairs.

The contract, with a duration of up to 25 years, builds upon investments by the A&M System and the state of Texas in growing new jobs in the burgeoning biopharmaceuticals industry.

The need for this advanced public health and biosecurity capability was identified following a comprehe

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading